HER2-low expression in breast oncology: treatment implications in the smart chemotherapy era
暂无分享,去创建一个
[1] A. Bardia,et al. LBA76 Overall survival (OS) results from the phase III TROPiCS-02 study of sacituzumab govitecan (SG) vs treatment of physician's choice (TPC) in patients (pts) with HR+/HER2- metastatic breast cancer (mBC) , 2022, Annals of Oncology.
[2] A. Bardia,et al. 214MO Sacituzumab govitecan (SG) efficacy in hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2–) metastatic breast cancer (MBC) by HER2 immunohistochemistry (IHC) status in the phase III TROPiCS-02 study , 2022, Annals of Oncology.
[3] M. Piccart,et al. Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer , 2022, npj Breast Cancer.
[4] A. Bardia,et al. Sacituzumab Govitecan in Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] G. Curigliano,et al. Navigating the HER2-Low Paradigm in Breast Oncology: New Standards, Future Horizons. , 2022, Cancer discovery.
[6] Sung-Bae Kim,et al. Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer , 2022, New England Journal of Medicine.
[7] A. Bardia,et al. 168P Sacituzumab govitecan (SG) efficacy in patients with metastatic triple-negative breast cancer (mTNBC) by HER2 immunohistochemistry (IHC) status: Findings from the phase III ASCENT study , 2022, Annals of Oncology.
[8] G. Curigliano,et al. Bystander effect of antibody–drug conjugates: fact or fiction? , 2022, Current Oncology Reports.
[9] A. Bardia,et al. Antibody–drug conjugates: Smart chemotherapy delivery across tumor histologies , 2021, CA: a cancer journal for clinicians.
[10] Sung-Bae Kim,et al. Interstitial Lung Disease Induced by Anti-ERBB2 Antibody-Drug Conjugates: A Review. , 2021, JAMA oncology.
[11] S. Loi,et al. ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.
[12] L. Carey,et al. Biomarker Analyses in the Phase 3 ASCENT Study of Sacituzumab Govitecan Versus Chemotherapy in Patients with Metastatic Triple-Negative Breast Cancer. , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.
[13] G. Curigliano,et al. Antibody–Drug Conjugates for the Treatment of Breast Cancer , 2021, Cancers.
[14] M. Piccart,et al. Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. , 2021, The New England journal of medicine.
[15] C. Criscitiello,et al. Antibody–drug conjugates in solid tumors: a look into novel targets , 2021, Journal of Hematology & Oncology.
[16] F. Cardoso,et al. HER2-Low Breast Cancer: Pathological and Clinical Landscape. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] Sung-Bae Kim,et al. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. , 2019, The New England journal of medicine.
[18] S. Paik,et al. NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] John M S Bartlett,et al. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. , 2018, Archives of pathology & laboratory medicine.
[20] John M S Bartlett,et al. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] T. Agatsuma,et al. DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1 , 2016, Clinical Cancer Research.
[22] M. Shah,et al. First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors , 2015, Clinical Cancer Research.
[23] Steven J. M. Jones,et al. Comprehensive molecular portraits of human breast tumours , 2013 .
[24] Steven J. M. Jones,et al. Comprehensive molecular portraits of human breast tumors , 2012, Nature.
[25] Y. Pommier. Topoisomerase I inhibitors: camptothecins and beyond , 2006, Nature Reviews Cancer.